Epsilogen | Evaluate

After Immunogen and Sutro, Bristol buys into the folate story

The deal puts more support behind targeting folate receptor α, a long troubled target, with antibody-drug conjugates.

December 04, 2020

Sutro bucks the folate trend

Competing folate receptor-targeting projects have recorded one failure after another, but Sutro scores a phase I win.

March 01, 2019

Immunogen fails to leap Forward

As doubts grow about targeting the folate receptor, Immunogen’s decision to press on with mirvetuximab soravtansine looks desperate.